Journal ArticleDOI
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study
Roberta De Angelis,Milena Sant,Michel P Coleman,Silvia Francisci,Paolo Baili,Daniela Pierannunzio,Annalisa Trama,Otto Visser,Hermann Brenner,Eva Ardanaz,Magdalena Bielska-Lasota,Gerda Engholm,Alice Nennecke,Sabine Siesling,Franco Berrino,Riccardo Capocaccia +15 more
Reads0
Chats0
TLDR
The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation.Abstract:
Summary Background Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE—the largest cooperative study of population-based cancer survival in Europe—has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were applied to all datasets. For patients diagnosed 2000–07, we calculated 5-year relative survival for 46 cancers weighted by age and country. We also calculated country-specific and age-specific survival for ten common cancers, together with survival differences between time periods (for 1999–2001, 2002–04, and 2005–07). Findings 5-year relative survival generally increased steadily over time for all European regions. The largest increases from 1999–2001 to 2005–07 were for prostate cancer (73·4% [95% CI 72·9–73·9] vs 81·7% [81·3–82·1]), non-Hodgkin lymphoma (53·8% [53·3–54·4] vs 60·4% [60·0–60·9]), and rectal cancer (52·1% [51·6–52·6] vs 57·6% [57·1–58·1]). Survival in eastern Europe was generally low and below the European mean, particularly for cancers with good or intermediate prognosis. Survival was highest for northern, central, and southern Europe. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon, and lung cancers. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation. Survival usually decreased with age, although to different degrees depending on region and cancer type. Interpretation The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe. Likely explanations of differences in survival between countries include: differences in stage at diagnosis and accessibility to good care, different diagnostic intensity and screening approaches, and differences in cancer biology. Variations in socioeconomic, lifestyle, and general health between populations might also have a role. Further studies are needed to fully interpret these findings and how to remedy disparities. Funding Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation, Cariplo Foundation.read more
Citations
More filters
Journal ArticleDOI
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Claudia Allemani,Hannah K. Weir,Helena Carreira,Rhea Harewood,Devon Spika,Xiao-Si Wang,Finian Bannon,Jane V Ahn,Christopher J. Johnson,Audrey Bonaventure,Rafael Marcos-Gragera,Charles A. Stiller,Gulnar Azevedo e Silva,Wanqing Chen,Olufemi Ogunbiyi,Bernard Rachet,Matthew J Soeberg,Hui You,Tomohiro Matsuda,Magdalena Bielska-Lasota,Hans H. Storm,Thomas C. Tucker,Michel P Coleman +22 more
TL;DR: The aim was to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control.
Journal ArticleDOI
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.
J. Ferlay,Murielle Colombet,Isabelle Soerjomataram,Tadeusz Dyba,Giorgia Randi,M Bettio,Anna Gavin,Otto Visser,Freddie Bray +8 more
TL;DR: The present estimates of the cancer burden in Europe alongside a description of the profiles of common cancers at the national and regional level provide a basis for establishing priorities for cancer control actions across Europe.
Journal ArticleDOI
Integrated genomic characterization of oesophageal carcinoma.
BC Cancer Agency,Brigham,KU Leuven,Tissue Source Sites: Analytic Biologic Services,Asterand Bioscience,BioreclamationIVT,Botkin Municipal Clinic,Cureline,Invidumed,Israelitisches Krankenhaus Hamburg,Ontario Tumour Bank +10 more
TL;DR: The authors' analyses identified three molecular subclasses of oesophageal squamous cell carcinomas, but none showed evidence for an aetiological role of human papillomavirus and these data provide a framework to facilitate more rational categorization of these tumours and a foundation for new therapies.
Journal ArticleDOI
Epidemiology of Prostate Cancer
TL;DR: There is no evidence yet on how to prevent prostate cancer; however, it is possible to lower the risk by limiting high-fat foods, increasing the intake of vegetables and fruits and performing more exercise.
Journal ArticleDOI
Global incidence of oesophageal cancer by histological subtype in 2012
TL;DR: These first global estimates of oesophageal cancer incidence by histology suggested a high concentration of AC in high-income countries with men being at much greater risk.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Book
International Classification of Diseases for Oncology
TL;DR: This list of diseases for oncology includes cancers of the central nervous system, as well as other types of diseases such as lymphoma, leukaemia, and so on.
Journal Article
The relative survival rate: a statistical methodology.
F Ederer,L M Axtell,S J Cutler +2 more
Journal ArticleDOI
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
Michel P Coleman,David Forman,Heather Bryant,John Butler,Bernard Rachet,Camille Maringe,Ula Nur,Elizabeth Tracey,Michael Coory,Juanita Hatcher,Colleen E. McGahan,D Turner,Loraine D. Marrett,ML Gjerstorff,Tom Børge Johannesen,Jan Adolfsson,Mats Lambe,Mats Lambe,Glenda Lawrence,David Meechan,Eva Morris,Richard Middleton,John Steward,Michael Richards +23 more
TL;DR: In this paper, the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival, was presented, where data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million adults diagnosed with primary colorectal, lung, breast, ovarian, or ovarian cancer during 1995-2007, with follow-up to Dec 31, 2007.
Journal ArticleDOI
EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary
Milena Sant,Tiiu Aareleid,Franco Berrino,M Bielska Lasota,P. M. Carli,Jean Faivre,Pascale Grosclaude,G. Hedelin,T Matsuda,Henrik Møller,T. Möller,Arduino Verdecchia,Riccardo Capocaccia,Gemma Gatta,Andrea Micheli,Mariano Santaquilani,Paolo Roazzi,D Lisi +17 more
TL;DR: EUROCARE-3 as mentioned in this paper analyzed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries and found that survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain).